Anti-MDA5 autoantibodies predict clinical dynamics of dermatomyositis following SARS-CoV-2 mRNA vaccination: a retrospective statistical analysis of case reports DOI Creative Commons
C. Klein, Annkristin Heine, Peter Brossart

et al.

Rheumatology International, Journal Year: 2024, Volume and Issue: 44(10), P. 2185 - 2196

Published: Aug. 27, 2024

Abstract Since the introduction of mRNA vaccines against SARS-CoV-2, induction autoimmunity by vaccination has been discussed. Several cases dermatomyositis (DM) associated with SARS-CoV-2 infection have reported. The question is whether there a common pathomechanism for DM this vaccination. aim review to analyse sample previously published case reports following COVID-19 indicators possible immune pathomechanism. In review, we summarised COVID-19. We considered report landscape as cumulative ( n = 32) and identified clinical molecular parameters in intersection statistically analysed effect these on development DM. MDA-5 antibodies seem play role autoantibody signature after MDA-5-positive more strongly interstitial lung disease/rapidly progressive disease (ILD/RP-ILD) than MDA-5-negative seems not be an increased risk malignancy, whereas malignancy. Our findings emphasize potential innate antiviral signalling pathways connecting autoantibodies appear predictive severe progression There association between paraneoplastic post-vaccination. Further studies are required uncover underlying mechanisms triggered

Language: Английский

Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress DOI

Xin Lu,

Qinglin Peng, Guochun Wang

et al.

Nature Reviews Rheumatology, Journal Year: 2023, Volume and Issue: 20(1), P. 48 - 62

Published: Dec. 6, 2023

Language: Английский

Citations

60
MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C) DOI
Paula David, Saptarshi Sinha,

Khizer Iqbal

et al.

EBioMedicine, Journal Year: 2024, Volume and Issue: 104, P. 105136 - 105136

Published: May 8, 2024

Citations

19
COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report DOI Creative Commons
Vasiliki Syrmou, Christos Liaskos, Niki Ntavari

et al.

Immunologic Research, Journal Year: 2023, Volume and Issue: 71(4), P. 537 - 546

Published: March 16, 2023

Abstract Several cases of vaccine-associated manifestations have been published including inflammatory myositis. Herein, we comprehensively review the literature on occasion case a woman with myositis following COVID-19 vaccination. A 67-year-old presented left arm edema, rash, and weakness after 2 nd dose BTN162b2 vaccine. Raised muscle enzymes markers edema MRI findings electromyogram established diagnosis. She was successfully treated methylprednisolone pulses, intravenous immunoglobulin, methotrexate, hydroxychloroquine. Cases myositis, dermatomyositis, or interstitial lung disease myositis-specific autoantibodies myositis-associated within 12 weeks from SARS-CoV-2 vaccination were included. malignancy, prior subsequent infection, preexisting myositis/interstitial (ILD)/dermatomyositis (DM), other connective tissue diseases excluded. From our search, 49 identified (mean age: 56.55 + 17.17 years), 59% women, while patients received ChAdOx1 vaccine, 27 BNT162b2, 8 mRNA-1273, 1 DB15806, Ad26.COV2.S (overall, 70% mRNA vaccines). Muscle involvement most common manifestation (79.5%), followed by skin (53%) ILD (34.6%), which more in m-RNA vaccinees. biopsy, findings, autoantibody profile varied significantly, successful immunosuppressive treatment applied cases. Inflammatory has well documented worldwide. Current evidence support pathogenic link is challenging due to significant variation clinical manifestations, radiological, histopathological, immunological features.

Language: Английский

Citations

25
Autoimmunity against melanoma differentiation–associated gene 5 induces interstitial lung disease mimicking dermatomyositis in mice DOI
Yuki Ichimura, Risa Konishi,

Tadatsune Iida

et al.

Proceedings of the National Academy of Sciences, Journal Year: 2024, Volume and Issue: 121(16)

Published: April 8, 2024

Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is characterized by amyopathic DM with interstitial lung disease (ILD). Patients anti-MDA5 antibody-associated ILD frequently develop rapidly progression and present high mortality rate in the acute phase. Here, we established a murine model of mediated autoimmunity against MDA5. Mice immunized recombinant MDA5 whole protein, accompanied complete Freund's adjuvant once week for four times, developed MDA5-reactive T cells antibodies. After injury induced intranasal administration polyinosinic-polycytidylic acid [poly (I:C)] mimicking viral infection, MDA5-immunized mice fibrotic representing prolonged respiratory inflammation changes 2 wk after poly (I:C)-administration, while control had quickly completely recovered from inflammation. Treatment anti-CD4 depleting antibody, but not anti-CD8 suppressed severity MDA5-induced ILD. Upregulation interleukin (IL)-6 mRNA, which was temporarily observed (I:C)-treated mice, mice. anti-IL-6 receptor antibody ameliorated These results suggested that exacerbates toll-like 3-mediated injury, prolongs resulting development IL-6 may play key role initiating this model.

Language: Английский

Citations

10
A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19 DOI Creative Commons
Koushan Kouranloo, Mrinalini Dey, Helen Elwell

et al.

Rheumatology International, Journal Year: 2023, Volume and Issue: 43(7), P. 1221 - 1243

Published: Feb. 14, 2023

A literature review on new-onset autoimmune connective tissue diseases (ACTDs) following COVID-19 is lacking. We evaluated potential associations between and the development of ACTDs. The "population" was adults with disease terms for ACTDs, including systemic lupus erythematosus (SLE), Sjogren's syndrome, sclerosis (SSc), idiopathic inflammatory myositis (IIM), anti-synthetase mixed CTD undifferentiated CTD, "intervention" as related terms. Databases were searched English-language articles published until September 2022. identified 2236 28 ultimately included. Of included patients, 64.3% female, a mean age 51.1 years. USA reported most cases (9/28). ACTD diagnoses comprised: 11 (39.3%) IIM (including four dermatomyositis); 7 (25%) SLE; (14.3%) syndrome; SSc; two (7.1%) other (one lupus/MCTD overlap). eight, patients that lupus/MCTD) had nephritis. average time from to diagnosis 23.7 days. third admitted critical care, one treatment haemophagocytic lymphohistiocytosis in SLE (14 sessions plasmapheresis, rituximab intravenous corticosteroids) nine due COVID-19. 80% went into remission treatment, while three (10%) died-one macrophage activation syndrome unreported causes. Our results suggest association notably young females, reflecting more comprehensive epidemiology. common our cohort IIM. aetiology mechanisms by which ACTDs emerge remain unknown require further research.

Language: Английский

Citations

23
The relationship between infectious agents and juvenile dermatomyositis: a narrative update from the pediatric perspective DOI Creative Commons
Chiara Sassetti,

Claudia Borrelli,

Martha Mazuy

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: April 10, 2024

Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy affecting children, being marked by chronic inflammation which mostly impacts on both skin and skeletal muscles; diagnostic criteria of JDM include an unforeseeable mixture clinical features, while treatment modalities commonly require corticosteroids or immunosuppressant agents. Although pathogenesis not completely understood, several infectious triggers have been linked to its priming via anecdotal reports related children. Pediatric cases recent-onset temporally associated disease power increased titers circulating antibodies a putative agent, including parasites, and/or detectable viral RNA bacterial DNA. With this narrative review we offer update about association with host infections, namely parvovirus B19, Epstein-Barr virus, Coxsackie human immune deficiency severe acute respiratory syndrome coronavirus 2,

Language: Английский

Citations

8
New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review DOI Creative Commons
Arvind Nune,

Victor Durkowski,

S. Sujitha Pillay

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(10), P. 1571 - 1571

Published: Oct. 8, 2023

A comprehensive, up-to-date systematic review (SR) of the new-onset rheumatic immune-mediated inflammatory diseases (R-IMIDs) following COVID-19 vaccinations is lacking. Therefore, we investigated demographics, management, and prognosis new R-IMIDs in adults SARS-CoV-2 vaccinations. literature search Medline, Embase, Google Scholar, LitCovid, Cochrane was conducted. We included any English-language study that reported R-IMID post-COVID-19 vaccination. total 271 cases were from 39 countries between January 2021 May 2023. The mean age patients 56 (range 18-90), most females (170, 62.5%). Most (153, 56.5%) received Pfizer BioNTech vaccine. Nearly 50% developed after second dose Vasculitis prevalent clinical presentation (86, 31.7%), followed by connective tissue disease (66, 24.3%). duration vaccine's 'trigger' 11 days. (220, 81.2%) corticosteroids; however, 42% (115) DMARDs such as methotrexate, cyclophosphamide, tocilizumab, anakinra, IV immunoglobulins, plasma exchange, or rituximab. Complete remission achieved 75 (27.7%), 137 (50.6%) improved treatment. Two died due to myositis. This SR highlights vaccines may trigger R-IMID; further epidemiology studies are required.

Language: Английский

Citations

16
Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience DOI Open Access
Fadi Kharouf, Ariel Kenig, Emilie Bohbot

et al.

Clinical and Experimental Rheumatology, Journal Year: 2023, Volume and Issue: unknown

Published: Jan. 13, 2023

Language: Английский

Citations

14
New-Onset MDA-5 Dermatomyositis in a Patient Following COVID-19 Vaccination: A Case Report DOI Open Access
Eleana Bolla, G. Fragoulis, Alexios Iliopoulos

et al.

Mediterranean Journal of Rheumatology, Journal Year: 2024, Volume and Issue: 35(1), P. 179 - 179

Published: March 1, 2024

Vaccination against Sars-CoV-2 has been proven to significantly reduce COVID-19 morbidity and mortality is therefore recommended for the general population, especially seniors with impaired immunity.However, it currently postulated that vaccines could rarely induce autoimmune diseases in previously healthy individuals.We report a case of new-onset anti-melanoma differentiation-associated protein 5 (anti-MDA5) antibody-positive dermatomyositis patient presenting rash fever following third dose vaccine.The laboratory testing revealed high titres anti-MDA-5 antibody chest computed tomography showed micronodular lesions ground glass opacities bilaterally.The was promptly treated corticosteroids, methotrexate, azathioprine, later started on rituximab due exacerbation along newly formed, diffuse skin ulcers.Our highlights potential immunogenicity need further reporting rare rheumatic syndromes possibly related disease vaccination.

Language: Английский

Citations

3
Outcome of COVID-19 in patients with idiopathic inflammatory myopathy during the Omicron wave in China: A longitudinal observational study DOI Creative Commons
Ying Li,

Xiaolan Tian,

Chao Sun

et al.

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(2), P. e0317319 - e0317319

Published: Feb. 10, 2025

Objective The coronavirus disease pandemic brought unknown challenges to patients with idiopathic inflammatory myopathy, who are often heavily immunosuppressed and have comorbidities. We aimed investigate the outcomes risk factors of in Chinese myopathy during Omicron wave. Methods This observational study included visited China-Japan Friendship Hospital. Data on baseline characteristics disease-related information were collected through medical records surveys, subsequently analysed. Results Overall, 204 identified; dermatomyositis was most common subtype. from 185 tested positive for severe acute respiratory syndrome 2 via polymerase chain reaction or antigen tests; these, 20 experienced a course disease, 9 died. All had myopathy-associated interstitial lung antibodies observed mortality anti-aminoacyl tRNA synthetase anti-MDA-5 antibodies. Furthermore, 45.0% group took > 15.0 mg prednisone daily before infection, significantly higher proportion than that non-severe group. Advanced age, mechanics’ hands, dyspnoea, chronic cough fever myositis, low lymphocyte count, serum albumin level, high D-dimer ferritin levels infection prominent disease. Albumin below 35.0 g/L above 306.8 ng/mL independent Conclusion did not worsen overall myopathy; however, specific identified, highlighting need targeted management strategies.

Language: Английский

Citations

0